Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 plus carboplatin phase 1 study in advanced solid tumors
NL-OMON56391Phase 1Recruiting
- Sponsor
- Debiopharm
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zedoresertib in Nonhematologic neoplasms, ovarian cancer, primary peritoneal cancer (PPC) and 1 more (3 arms), sponsored by Debiopharm. Primary endpoints: Recommended phase 2 dose, Safety and tolerability and 1 more. Started Jul 2019; status: recruiting.
02
Drugs
zedoresertib
03
Conditions
Nonhematologic neoplasmsovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON56391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56391.